Leo Pharma

LEO Pharma Strengthens Its Commercial Organization  

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Science, Leadership, Regionalism (international relations), Tesco international operations, Time, Research, Tralokinumab, EBITDA, Global leadership, Leo Pharma, CEO, Novo Nordisk, Growth, Patient, Region, LEO, Efficiency, GLT, Dermatology, DKK, Management, Communications satellite, Fine chemical

The commercial responsibilities in the Global Leadership Team (GLT) are consolidated, thereby reducing the number of commercial members.

Key Points: 
  • The commercial responsibilities in the Global Leadership Team (GLT) are consolidated, thereby reducing the number of commercial members.
  • The new lead role will be held by Executive Vice President Becki Morison, who joined LEO Pharma in October 2020 as Executive Vice President Global Therapeutic & Value Strategy.
  • The new region will be headed by Executive Vice President Brian Hilberdink, who joined LEO Pharma in February 2022 as President of LEO Pharma Inc. in the U.S.
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

LEO Pharma Leverages Veeva Link for Key People to Expand Engagement with Scientific Experts

Retrieved on: 
Wednesday, April 27, 2022
People, Cloud, Marketing, Leo Pharma, Dermatology, Research, Align Biopharma, Professional corporation, Veeva Systems, Form 10-K, Health, Solution, SEC, NYSE, Partnership, Industry, Quality of life, Architecture, Fine chemical, Risk management

PLEASANTON, Calif., April 27, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that it has expanded its partnership with LEO Pharma, a global leader in medical dermatology, to drive relevant discussions with the scientific community using Veeva Link for Key People, a real time intelligence application from the Veeva Link family of data products. Leveraging Link for Key People enables LEO Pharma's medical and sales teams to improve engagement efforts with medical experts in the dermatology community. 

Key Points: 
  • Link for Key People will help us deepen relationships with known experts and identify new experts to foster scientific exchange that advances patient care."
  • With plans to launch new treatments every two to three years, LEO Pharma's medical affairs team plays a vital role in engaging with scientific leaders globally.
  • Veeva Link is part of Veeva Data Cloud , a suite of data products built on a common architecture.
  • For more on Veeva Link, visit: veeva.com/VeevaLink
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
    Veeva is the global leader in cloud software for the life sciences industry.

LEO Pharma Leverages Veeva Link for Key People to Expand Engagement with Scientific Experts

Retrieved on: 
Wednesday, April 27, 2022
People, Cloud, Marketing, Leo Pharma, Twitter, Dermatology, Research, Align Biopharma, Professional corporation, Veeva Systems, Form 10-K, Health, Solution, SEC, NYSE, Partnership, Industry, Quality of life, Architecture, Fine chemical, Medical device, Risk management

BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that it has expanded its partnership with LEO Pharma, a global leader in medical dermatology, to drive relevant discussions with the scientific community using Veeva Link for Key People, a real time intelligence application from the Veeva Link family of data products. Leveraging Link for Key People enables LEO Pharma's medical and sales teams to improve engagement efforts with medical experts in the dermatology community.

Key Points: 
  • Leveraging Link for Key People enables LEO Pharma's medical and sales teams to improve engagement efforts with medical experts in the dermatology community.
  • Link for Key People will help us deepen relationships with known experts and identify new experts to foster scientific exchange that advances patient care."
  • "Considering LEO Pharma's rapid pace of clinical innovation, it's no surprise the company's medical and commercial teams are leading the way in precision engagement," said Kilian Weiss, general manager for Veeva Link.
  • Veeva Link is part of Veeva Data Cloud , a suite of data products built on a common architecture.

LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative

Retrieved on: 
Thursday, April 21, 2022
Science, Other Energy, Biotechnology, Research, Pharmaceutical, Environment, Health, Energy, World Wide Fund for Nature, Pharma, United Nations Global Compact, WWF, Carbon, LEO, Climate change, Leo Pharma, CDP, Dermatology, Research, World Resources Institute, Health, Targets, Science, Paris, Silent Scope 3, Goal, Patient, DKK, Review, Environment, Solution, WRI, Paris Agreement, Fine chemical, Renewable energy

LEO Pharma is proud to announce the validation of its Scope 1 & 2 and Scope 3 targets by the Science Based Targets initiative (SBTi)1.

Key Points: 
  • LEO Pharma is proud to announce the validation of its Scope 1 & 2 and Scope 3 targets by the Science Based Targets initiative (SBTi)1.
  • We congratulate LEO Pharma on setting science-based targets consistent with limiting warming to 1.5C, the most ambitious goal of the Paris Agreement," said Alberto Carrillo Pineda, Managing Director, Science Based Targets at CDP, one of the Science Based Targets initiative partners.
  • "By setting ambitious science-based targets grounded in climate science, LEO Pharma is taking action to prevent the most damaging effects of climate change."
  • Value chain (Scope 3): LEO Pharma commits to ensuring that 75% of our suppliers by emissions have set science-based targets by 2026.

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Therapy, Trust law, Bacteriophage, European Commission, MD, Royal commission, Technology, Johnson & Johnson, Time, US, UCB, National, Novo Nordisk Foundation, Investigational New Drug, United States Department of Defense, Bacteria, Â, Mayo Clinic, Boehringer Ingelheim, NIH, Eli Lilly and Company, DFO, European Investment Bank, World Health Organization, Merck Group, AMR, Multimedia, Doctor of Philosophy, World, Wellcome Trust, FDA, Fund, Patient, Partnership, Daiichi Sankyo, List of international sports federations, Medication, Leo Pharma, APT, Novo Nordisk, Infection, Pharmaceutical industry, Antibiotics, Takeda, GlaxoSmithKline, Eisai, Amgen, Pfizer, Lundbeck, Bayer, Merck, Novartis, Teva, Chugai Pharmaceutical Co., Shionogi

Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.

Key Points: 
  • Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.
  • View the full release here: https://www.businesswire.com/news/home/20220404005289/en/
    We are very pleased to welcome the AMR Action Fund as an investor, stated Greg Merril, Chief Executive Officer and Co-Founder of APT.
  • In addition to their capital, the AMR Action Fund adds significant strategic value, including advisory and scientific support.
  • The AMR Action Fund is the worlds largest public-private partnership investing in antibiotics, antifungals, and other antimicrobial treatments.

LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting

Retrieved on: 
Friday, March 25, 2022
FDA, Health, Science, Pharmaceutical, Research, Conjunctivitis, LEO, Headache, IGA, Tralokinumab, Drug, Itch, Allergy, Dermatitis, Anaphylaxis, AD, AAD, Respiratory tract, Adult, Skin, Atopic dermatitis, DLQI, Observation, Patient, Leo Pharma, Food, Poster, Breast milk, American Academy of Dermatology, MD, Quality of life, Safety, Vitamin, DDI, MBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, Psoriasis Area and Severity Index, Dermatology Life Quality Index, TCS, AES, FDA, AE, Hypersensitivity, Eczema Area and Severity Index, Bureau of Oceans and International Environmental and Scientific Affairs, Tell, Syringe, NRS, Pharmaceutical industry, Vaccine, Health insurance, Birth control, THE ECZTEND - LONG-TERM EXTENSION (LTE), ATOPIC DERMATITIS, ADBRY™ (TRALOKINUMAB-LDRM), LEO PHARMA

LEO Pharma A/S, a global leader in medical dermatology, today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD).
  • The latest interim safety and efficacy findings are similar to earlier reports and continue to reinforce the rationale for treatment specifically targeting IL-13 in adult patients with moderate-to-severe atopic dermatitis.
  • The modified non-responder imputation and last observation carried forward analyses were also reported in the poster and results were comparable across the three analyses.
  • Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board

Retrieved on: 
Wednesday, March 2, 2022
Eli Lilly and Company, Sangamo Therapeutics, COVID, Patient, Vaccine, Research, Industry, Regulation, Regulation Fair Disclosure, Investor, Infection, Security (finance), U.S. Securities and Exchange Commission, Eli Lilly, University, Board of directors, Forma, Pandemic, Southern Methodist University, PRDS, Webcast, Board, Leo Pharma, Company, COVID-19, Time, Methodist University, Acquisition, Derek Wiggan, Stiefel Laboratories, Onyx Pharmaceuticals, Disclosure, Severe acute respiratory syndrome coronavirus 2, GLOBE, NASDAQ, Management, Pharmaceutical industry, Director, Pardes, Pharmacy

CARLSBAD, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced the appointment of Thomas G. Wiggans as Chief Executive Officer and Chair of the Board of Directors. Uri Lopatin, M.D. will remain on the Board of Directors and continue to play an active role in the company’s research and development activities as Chief Scientific & Strategic Advisor. In addition, Mark Auerbach will transition from Chairman to Board Director.

Key Points: 
  • "Its my privilege to welcome Tom as Pardes Biosciences new Chief Executive Officer and Chairman of its Board of Directors.
  • I commend the Pardes team for their commitment, expertise, and accomplishments, said Tom Wiggans, Chief Executive Officer and Chair of Pardes Biosciences.
  • Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., Cymabay Therapeutics Inc., and Forma Therapeutics Holdings, Inc.
  • Accordingly, investors should monitor Pardes Biosciences Investors website, in addition to following Pardes Biosciences press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcast.

LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States

Retrieved on: 
Thursday, February 17, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, History, Patient, DKK, The arts, Science, Dermatology, LEO, Leo Pharma, Novo Nordisk, Pharma, FDA, Academy of Television Arts & Sciences, Senior, Research, Corporation, Skin, Fine chemical, Management

LEO Pharma A/S, a global leader in medical dermatology, today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.
  • Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.
  • Prior to joining Novo Nordisk in the U.S. as a Senior Vice President, Brian Hilberdink served as President of Novo Nordisk Canada Inc. and Corporate Vice President in Global Marketing of Novo Nordisk A/S in Denmark.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Medable Acquires Mobile Applications from LEO Pharma, Expands Global Engineering Team and European Presence

Retrieved on: 
Wednesday, February 2, 2022
Health, Pharmaceutical, Mobile, Wireless, Technology, Clinical Trials, CEO, Patient, Tufts Center for the Study of Drug Development, Skin, LEO, Â, Psychiatry Innovation Lab, Intelligence, Technology, Triage, Research, Dermatology, Drug development, Science, Acquisition, Smartphone, Leo Pharma, DKK, Software, Pharmaceutical industry, Medicine, Zurich metropolitan area, Medable, LEO Pharma, MEDABLE, LEO PHARMA

As part of the agreement with LEO Pharma A/S (owner of LEO Innovation Lab), Medable will take over the Omhu mobile applications and a talented team of 38 people with significant experience in digital health and artificial intelligence.

Key Points: 
  • As part of the agreement with LEO Pharma A/S (owner of LEO Innovation Lab), Medable will take over the Omhu mobile applications and a talented team of 38 people with significant experience in digital health and artificial intelligence.
  • The acquisition expands Medables global engineering talent and gives Medable a third location in Europe, building on its European headquarters in Dublin, Ireland launched last July, along with a Switzerland office outside the Greater Zurich area established last fall.
  • Were thrilled to add Omhus patient-centered solutions to our platform, and we welcome the innovative and talented Omhu team to Medable.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

AMR Action Fund Appoints Scientific Advisory Board

Retrieved on: 
Tuesday, February 1, 2022
European Investment Bank, Therapy, Novo Nordisk Foundation, Royal commission, University, US, Merck Group, Partnership, Trust law, Medication, AMR, Public health, UCB, CEO, Wellcome Trust, Decision-making, Mortality, Global health, Coronavirus Scientific Advisory Board (Turkey), World, Michigan State University, Research and development, Investment, Eli Lilly and Company, European Commission, Fund, Daiichi Sankyo, VP, Leo Pharma, List of international sports federations, Solution, Novo Nordisk, MBBS, Patient, MD, Johnson & Johnson, Boehringer Ingelheim, World Health Organization, SAB, Organ transplantation, Pharmaceutical industry, Amgen, Lundbeck, Shionogi, GlaxoSmithKline, Bayer, Pfizer, Novartis, Takeda, Chugai Pharmaceutical Co., Teva, Eisai, Merck

BOSTON, Feb. 1, 2022 /PRNewswire/ --The AMR Action Fund, the world's largest public-private partnership investing in the development of new antibiotics, today named nine appointees to its independent Scientific Advisory Board (SAB).

Key Points: 
  • BOSTON, Feb. 1, 2022 /PRNewswire/ --The AMR Action Fund, the world's largest public-private partnership investing in the development of new antibiotics, today named nine appointees to its independent Scientific Advisory Board (SAB).
  • The appointment of the advisory board members marks a key step for the Fund as it prepares to make its first investments.
  • "The experts on our Scientific Advisory Board bring diverse perspectives and extensive experience in antibiotic development and global health that will bolster our diligence efforts and help prioritize treatments that deliver the greatest benefits to patients," said Henry Skinner, CEO of the AMR Action Fund.
  • "I am delighted that this prestigious group of experts from around the world has joined the AMR Action Fund's Scientific Advisory Board," said John Rex, MD, SAB Chair.